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Corticosteroids have been the mainstay of uveitis therapy. When intraocular 
inflammation is unresponsive to steroids, or steroid related side effects become a 
concern, steroid-sparing medications may be administered which can be classified 
into immunosuppressive and immunomodulatory agents. Uveitis treatment can 
be delivered systemically, topically, periocularly or intraocularly. All of the above 
mentioned medications can entail significant systemic side effects, particularly if 
administered for prolonged durations, which may become treatment-limiting. Some 
medications, particularly hydrophobic compounds, may poorly cross the blood–retinal 
barrier. Topical medications, which have the least side effects, do not penetrate 
well into the posterior segment and are unsuitable for posterior uveitis which is 
often sight-threatening. Intraocular or periocular injections can deliver relatively 
high doses of drug to the eye with few or no systemic side effects. However, such 
injections are associated with significant complications and must often be repeated at 
regular intervals. Compliance with any form of regular medication can be a problem, 
particularly if its administration is associated with discomfort or if side effects are 
unpleasant. To overcome the above-mentioned limitations, an increasing number of 
sustained-release drug delivery devices using different mechanisms and containing 
a variety of agents have been developed to treat uveitis. This review discusses 
various current and future sustained-release ophthalmic drug delivery systems for 
treatment of uveitis.
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INTRODUCTION
Uveitis is an umbrella term covering a large group 
of ocular inflammatory disorders that primarily 
involve the uvea but may also affect adjacent 
tissues. In intermediate uveitis, the primary 
focus of inflammation is the vitreous, whereas 
in posterior uveitis, the retina or choroids are 
afflicted.1 Uveitis may also be categorized as 
infectious and noninfectious. Intermediate 
and posterior uveitis may occur as a primary 
ocular process or can be the manifestation of 
a systemic disease. They account for much 
of the visual loss associated with uveitis due 
to the high rate of complications including 
cystoid macular edema (CME), subretinal and 
epiretinal fibrosis, retinal detachment, optic 
atrophy, glaucoma, and cataracts. A European 
study involving over 500 patients with posterior 
uveitis reported that up to 35% suffered from Drug Delivery Devices; Haghjou et al
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blindness or visual impairment.2 Furthermore, 
10-15% of blindness in the USA is attributed 
to uveitis.3
The main goal in the treatment of uveitis is 
to eliminate intraocular inflammation, relieve 
discomfort and prevent visually significant 
complications. When anti-inflammatory agents 
are given systemically, they often need to be 
administered at high doses over long periods 
to achieve adequate anti-inflammatory effect. 
Corticosteroids are the mainstay of uveitis 
therapy; however, treatment may not be fully 
effective, or side effects may be treatment-
limiting. The side effects of chronic systemic 
corticosteroid administration have been well 
documented and include changes in general 
appearance, weight gain, systemic hypertension, 
hyperglycemia, gastritis, opportunistic infections, 
and psychosis. Under such circumstances it is 
often necessary to switch to alternative drugs. 
These agents can be broadly termed steroid-
sparing drugs since they can either reduce the 
required dose of corticosteroids or may replace 
them altogether. Broadly speaking, steroid-
sparing medications can be classified into 
immunosuppressive and immunomodulatory 
agents. Immunosuppressive agents include 
antimetabolites, such as methotrexate, 
azathioprine and mycophenolate mofetil; and 
alkylating agents, such as cyclophosphamide 
and chlorambucil. Immunomodulatory 
agents include calcineurin inhibitors such as 
cyclosporin A (CsA) and tacrolimus (FK506), 
and biological agents such as infliximab and 
adalimumab.
Uveitis treatment can be delivered topically, 
periocularly, intraocularly or systemically. There 
are problems common to all delivery routes 
and some specific to each of them.
All of the previously outlined medications 
have significant systemic side effects particularly 
if used for prolonged periods of time which 
can become treatment-limiting. Many 
immunosuppressive drugs are teratogenic and 
contraindicated during pregnancy; some of 
them may even prevent conception. Most side 
effects become apparent during treatment and 
can damage specific organs such as the liver 
and kidneys, the function of which needs to 
be continuously monitored during the course 
of treatment. However, certain side effects 
such as osteoporosis and lymphoproliferative 
malignancies may not become apparent until 
years after treatment has been terminated. 
Osteoporosis is particularly related to 
corticosteroid use even at low doses. Rapid 
bone loss has been associated with corticosteroid 
doses >5 mg employed for three months or more. 
Long-term immunosuppression may increase 
the risk of cancer, particularly solid tumors 
and lymphomas. This increased cancer risk 
is probably the result of reduction in normal 
immune surveillance or due to the direct effect 
of the medication on DNA.
Compliance with any form of regular 
medication can be a problem, particularly if its 
administration is associated with discomfort or 
if side effects are unpleasant. Some medications, 
particularly hydrophobic drugs, may cross 
the blood–retinal barrier poorly, which is 
an important consideration for all delivery 
systems except for intraocular injections. Topical 
medications, which entail the least side effects, 
do not penetrate into the posterior segment and 
are unsuitable for posterior uveitis, which is 
often sight-threatening.
Intraocular or periocular injections can 
deliver a relatively high dose of drug to the eye 
with few or no systemic side effects. However, 
these methods may be associated with significant 
complications and often need to be repeated at 
regular intervals. Repeated periocular injections 
may also lead to complications including globe 
perforation, orbital fibrosis and ptosis.4
To overcome the abovementioned 
limitations, an increasing number of sustained-
release drug delivery devices using different 
mechanisms and containing a variety of agents 
have been developed to treat uveitis.
This article reviews major drug delivery 
technologies currently in clinical trials or at 
experimental stages for treatment of uveitis.
SOLID IMPLANTS
Retisert
In April 2005, Retisert (Bausch & Lomb, Drug Delivery Devices; Haghjou et al
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Inc., Rochester, NY, USA) received fast-
track approval by the US Food and Drug 
Administration (FDA) as an orphan drug for 
treatment of chronic noninfectious uveitis 
affecting the posterior segment. This type of 
uveitis is extremely damaging because it tends to 
strike people in their prime working years and 
unless controlled, can lead to tissue destruction 
and vision loss. Retisert is a sterile implant 
that releases the potent anti-inflammatory 
corticosteroid fluocinolone acetonide (molecular 
weight, 452.5 Da).
Fluocinolone acetonide is a white crystal-
line powder, insoluble in water but soluble 
in methanol. Each Retisert consists of a 
tablet containing 0.59 mg of the active agent, 
fluocinolone acetonide, and the following 
inactive ingredients: microcrystalline cellulose, 
polyvinyl alcohol, and magnesium stearate. The 
drug release rate is 0.6µg/day initially, which 
decreases over the first month to a steady state 
between 0.3-0.4 µg/day up to approximately 
30 months.
Retisert is about the size of a grain of rice 
and consists of a tablet encased in a silicone 
elastomer cup containing a release orifice and a 
polyvinyl alcohol (PVA) membrane positioned 
between the tablet and the orifice (Fig. 1). The 
silicone elastomer cup assembly is attached to 
a PVA suture strut with silicone adhesive. The 
liquid environment of the vitreous hydrates 
the pellet and puts some drug in the solution 
which crosses the implant’s orifice. Retisert 
has linear release characteristics with no bolus 
release in the beginning.
Use of a Retisert becomes more of a 
consideration when there is intermediate or 
posterior uveitis. First it must be ascertained that 
the uveitis is noninfectious and not associated 
with a systemic condition with multi-organ 
involvement such as sarcoidosis. The device 
is contraindicated for infectious uveitis such 
as syphilis, toxoplasmosis, cytomegalovirus 
retinitis, and candidiasis. It may be indicated for 
noninfectious etiologies including sarcoidosis, 
Behcet’s disease, and “white dot” syndromes 
such as multifocal choroiditis or birdshot 
chorioretinopathy.
It is recommended that treatment of 
uveitis patients be initiated with a course of 
oral steroids, primarily prednisolone. In this 
way, it can be confirmed that the uveitis is 
noninfectious. It is much easier to discontinue 
prednisone as compared to remove a Retisert 
implant if the uveitis is revealed to be infectious. 
Retisert is also used off-label for treatment of 
diabetic macular edema.5
This fluocinolone acetonide implant has 
been studied in 3 multicenter, randomized, 
prospective, phase III controlled clinical trials. 
Two of them were double-masked and compared 
2 doses (0.59 mg vs. 2.1 mg) of the implant in 
one eye compared to no treatment in control 
eyes.6,7 By continuous delivery of therapy to 
a localized area, Retisert can reduce the rate 
of recurrence of uveitis. During the clinical 
trials leading to FDA approval, the rate of 
recurrence decreased from 54% before to 7% 
after Retisert implantation; and from 40% 
before to 14% after implantation of the device 
in two different trials. Retisert also stabilized 
or improved visual acuity in 80% of patients. 
Retisert reduced the percentage of patients 
requiring systemic corticosteroid therapy from 
47-63% to 5-10% after 34 weeks.
Pavesio et al8 performed an open-label trial 
comparing the 0.59 mg implant vs. standard of 
care (SOC). It was observed that eyes receiving 
Retisert experienced delayed onset and a lower 
rate of recurrence of uveitis as compared to 
SOC eyes (18.2% vs. 63.5%). Common ocular 
adverse events in implanted eyes included 
elevated intraocular pressure (IOP) requiring 
IOP-lowering surgery (21.2%) and cataracts 
requiring extraction (87.8% of phakic eyes). 
The authors concluded that Retisert may be 
considered a reasonable alternative when 
patients are intolerant or refractory to systemic 
or topical therapy. No non-ocular adverse events 
were observed in the implant group, whereas  Figure 1. Retisert implant.Drug Delivery Devices; Haghjou et al
320 JOURNAL OF OPHTHALMIC AND VISION RESEARCH 2011; Vol. 6, No. 4
such events occurred in 25.7% of subjects in 
the SOC group. Therefore, implantation may 
be considered for patients in whom systemic 
steroid-related side effects are more frequent 
and/or severe than ocular adverse effects.9 
Patients should be informed about potential 
adverse effects of the fluocinolone acetonide 
intravitreal implant including cataracts, 
increased intraocular pressure or hypotony, 
endophthalmitis and need for additional 
procedures. Because of the differing benefits 
and risks of treatment with intravitreal implants 
in comparison with systemic therapy, patients 
should make an informed choice between 
such treatments. Some patients and insurance 
companies may be taken aback by Retisert’s 
$18,000 price tag. But education regarding 
the even higher cumulative cost of alternative 
treatments could facilitate acceptance by patients 
and reimbursement by insurance companies.
The “Multicenter Uveitis Steroid Treatment” 
(MUST) trial, sponsored by US National 
Institute of Health, is currently evaluating 
the effectiveness of Retisert as compared to 
conventional therapy (oral corticosteroids) for 
management of posterior uveitis in 400 patients 
at 20 sites throughout North America. This 
five-year study is presently recruiting patients.
Iluvien (Medidur)
Inflammation in the posterior segment may 
lead to macular edema and other retinal 
complications. Iluvien, previously known as 
Medidur FA (Alimera Sciences, Alpharetta, GA, 
USA), is an injectable non-erodible intravitreal 
device for treatment of diabetic macular edema 
(DME)10 which is a common complication of 
diabetic retinopathy and a leading cause of 
visual loss in subjects less than age 65. Similar 
to Retisert, Iluvien also contains fluocinolone 
acetonide (180 µg). Unlike Retisert however, 
Iluvien is injected into the eye as an office 
based procedure using a proprietary inserter 
with a 25-gauge needle, which allows a self-
sealing wound. The method of administration 
is similar to an intravitreal injection. Iluvien 
is a tiny cylindrical polyimide tube, 3.5mm in 
length and 0.37mm in diameter and releases 
a low dose of 0.23–0.45 µg/day fluocinolone 
acetonide for 18 to 36 months after injection 
(Fig.2). Iluvien is non-erodible and remains in 
the vitreous cavity even after drug release has 
been exhausted. Therefore, patients requiring 
repeated injections may end up with multiple 
devices trapped in the vitreous base for an 
indefinite period of time.
Iluvien may have a more favourable ocular 
hypertension side-effect profile as compared to 
Retisert. This may have to do with the position 
of these implants relative to the ciliary body 
and/or the trabecular meshwork.
Two different models of the device releasing 
high dose (0.45 µg/day) and low dose (0.23 
µg/day) active component have been designed 
for 18 and 36 months of drug release and are 
currently being investigated in two global 
phase 3 pivotal clinical trials involving 956 
patients which has been granted “fast track” 
by the FDA.
Surodex
Surodex (Allergan, Inc., Irvine, CA, USA) is 
a rod-shaped biodegradable matrix implant 
1.0×0.5 mm in size consisting of dexamethasone 
(molecular weight, 392.47) and poly lactide-
co-glycolide acid (PLGA) with hydroxypropyl 
methylcellulose (HPMC) which provides 
sustained drug release at a constant rate of 60 
µg over 7–10 days.11
The implant is inserted into the anterior 
chamber following cataract surgery to control 
postoperative inflammation.12 Surodex does not 
require suture fixation and is well tolerated.13 
In cataract patients, Surodex has been shown 
to reduce anterior chamber cell and flare in 
the postoperative period and to have an anti-
Figure 2. Iluvien implant shown on a human finger to 
indicate size.Drug Delivery Devices; Haghjou et al
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inflammatory effect at least as good as that of 
topical steroids.14 In another study, Surodex 
was implanted in the anterior chamber of 
rat eyes after induction of acute endotoxin 
induced uveitis (EIU) and chronic experimental 
autoimmune uveitis (EAU). Both acute and 
chronic inflammatory reactions were markedly 
inhibited in eyes receiving Surodex implants.15
Ozurdex (Posurdex)
Ozurdex is an intravitreal implant containing 
0.7 mg dexamethasone in a NOVADUR solid 
polymer drug delivery system. Ozurdex is 
preloaded into a single-use, specially designed 
applicator to facilitate injection of the rod-shaped 
implant directly into the vitreous cavity (Fig. 3).
The NOVADUR system contains PLGA 
intravitreal polymer matrix. The PLGA matrix 
slowly degrades to lactic acid and glycolic 
acid, meaning that when the active agent is 
consumed, degradation products are water 
and carbon dioxide, leaving no residue in the 
eye (Fig. 4).
Ozurdex is preservative-free and was 
initially called Posurdex; it has a history dating 
back almost a decade. Allergan partnered in 
2001 with the original developer of the implant, 
Oculex, and then purchased this company in 
2003. Ozurdex was approved for treatment of 
macular edema following branch or central 
retinal vein occlusion (RVO) in June 2009, with 
approval for additional indications anticipated.16 
Allergan, Inc. has completed a phase 3 trial of 
Ozurdex for treatment of ocular inflammation 
in the setting of posterior and intermediate 
uveitis. The drug is currently under FDA review 
for this indication. Clinical data for uveitis is 
promising and once approved, Ozurdex will 
be a valuable option for uveitis.
The implant is placed via a 22-gauge 
applicator into the vitreous cavity. It can 
deliver dexamethasone for up to six months 
with a relatively mild side effect profile.17 
Some increase in IOP, usually peaking around 
day 60, has been observed which returns to 
baseline by month six. Maximum effectiveness, 
as measured in pivotal clinical trials, occurs 
between 60 and 90 days.
Ozurdex is particularly effective in 
vitrectomized eyes, where traditional intravitreal 
injections clear too quickly to be of much use.
I-vation
Based on experimental studies performed by 
Machemer, Peyman and others, as well as 
clinical observations, intravitreal injections of 
triamcinolone acetonide (TA) have increasingly 
been used for treatment of uveitis. TA (molecular 
weight, 434.5 Da) is designated chemically as 
9-fluoro-11b,16a,17,21-tetrahydroxypregna-1, 
4-diene-3,20-dione cyclic 16,17-acetal with 
acetone. The empirical formula is C24H31FO6.
In order to achieve sustained therapeutic 
levels of TA and to reduce the frequency of 
intravitreal injections, different implantable 
devices or injectable systems have been under 
investigation. However no sustained-release TA 
device is yet commercially available.18 Figure 3. Ozurdex dexamethasone intravitreal implant 
and its applicator.
Figure 4. Ozurdex’s biodegradable matrix three weeks 
after implantation.Drug Delivery Devices; Haghjou et al
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SurModics Inc. has designed a delivery 
system using I-vation technology capable of 
delivering TA on a sustained-release basis. 
The I-vation intravitreal TA implant consists 
of three components: a helix-shaped non-
ferrous metallic scaffold, a cap attached to the 
helix, and a drug-loaded polymer coating that 
encapsulates the helix (Fig. 5). The polymers are 
polymethylmethacrylate and poly- ethylene-co-
vinyl acetate. The helical shape of the scaffold 
maximizes the surface area available for drug 
coating and enables suture-less anchoring of 
the implant against the sclera. The thin cap 
is designed to reside under the conjunctiva. 
Insertion of the implant requires conjunctival 
cut-down and placement in an operating room 
through a 0.5-mm needle stick. The delivery 
system is non-biodegradable and remains in 
place after drug release is completed.
The I-vation platform offers a great deal 
of versatility and flexibility for formulation 
and pharmacokinetic control. The device is 
implanted through a 25-gauge needle stick and 
is self-anchoring within the sclera. I-vation is 
an example illustrating the risks associated 
with the development of sustained-release 
devices. I-vation was designed to deliver 
925µg TA over a period of up to two years. 
A phase 1 trial including 30 patients showed 
reduction in DME at 24 months. However, when 
study data released in 2008 favored focal/
grid photocoagulation over preservative-free 
intravitreal TA for treatment of DME, the phase 
2b I-vation trial was suspended.19
Vitrasert
The Vitrasert reservoir-type device, currently 
marketed by Bausch+Lomb, was developed by 
Paul Ashton, P. Andrew Pearson, and Thomas 
Smith at the University of Kentucky. It is the 
first implantable ganciclovir delivery device 
approved by the FDA in 1996 for treatment of 
cytomegalovirus CMV retinitis20 (Fig. 6). The 
device is composed of drug and polymeric 
coats of polyvinyl alcohol (PVA) and ethylene 
vinyl acetate (EVA). PVA, a permeable polymer, 
regulates the rate of ganciclovir release and 
EVA, an impermeable polymer, limits the 
surface area of the device through which 
the active agent can be released. The device 
has shown to have no initial burst effect. 
Currently, the same type of implant containing 
dexamethasone21, fluocinolone acetonide22, or 
cyclosporine23 is being tested for treatment of 
severe uveitis.
The commercially available device is 
relatively large; it requires a 4–5mm sclerotomy 
at the pars plana for implantation and releases 
the drug for 5 to 8 months. Since it is non-
biodegradable, the drug-depleted device needs 
to be removed during a second procedure in 
order to implant another device if required.
Figure 5. I-vation sustained drug delivery system.
Figure 6. Front view of Vitrasert on the left and the 
schematic on the right.Drug Delivery Devices; Haghjou et al
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Cyclosporine Devices
While systemic and local corticosteroids are 
often effective in treating uveitis, an alternative 
treatment may be required in eyes with a 
history of steroid-induced glaucoma or those 
refractory to steroid therapy.
Cyclosporin A (CsA) is a naturally occurring 
hydrophobic macrolide produced by soil fungi 
and a potent immunosuppressive agent that 
selectively suppresses T-cell activation by 
inhibiting the phosphatase action of calcineurin, 
thereby suppressing transcription of interleukin 
2 and other early phase T-cell activation genes.24 
Such inhibition prevents clonal expansion of 
helper and cytotoxic T-cells. CsA also prevents 
chemotaxis of inflammatory cells, particularly 
that of eosinophils. Peak CsA blood levels are 
reached six hours after ingestion; the drug is 
metabolized and concentrated by the cytochrome 
P450 microsomal system in the liver.
CsA penetrates the eye poorly when 
administered topically.25 Accordingly, topical 
CsA is not generally administered for control of 
intraocular inflammation. In contrast, moderate 
intraocular CsA levels are achieved with oral 
and systemic administration.26
Side effects of systemic CsA may include 
oral ulceration and gingivitis, hypertrichosis, 
malaise, headaches, muscle cramps, and 
gastrointestinal disturbance. Serious side effects 
such as nephrotoxicity and hypertension may 
be treatment-limiting.27
Prolonged use of cyclosporine, and thus 
good patient compliance, is required to 
adequately control intraocular inflammation. 
Direct intraocular injection of cyclosporine has 
been shown to control intraocular inflammation 
in an animal model of uveitis.28 However, the 
half-life of intravitreal cyclosporine is short 
which limits its effectiveness in chronic forms 
of uveitis.29
Gilger and coworkers30 described a discoid 
intravitreal device developed for the constant 
release of cyclosporine (CsA) in inflammatory 
episodes of uveitis in horses. This was 
accomplished by monitoring clinical signs and 
intraocular damage; and measuring cellular 
infiltrates, T-lymphocyte counts and transcribed 
cytokine specific mRNA. Nine healthy horses 
were immunized peripherally with H37RA-
mTB antigen twice, and then received 25mg 
of H37RA-mTB antigen intravitreally in the 
right eye and an equal volume of balanced 
salt solution in the left eye. Two weeks later, 
the animals randomly received either the CsA-
loaded device or a placebo in both eyes. One 
week after implantation of the devices, 25mg 
of H37RA-mTB antigen was re-injected into 
the right eye of each animal. Clinical signs of 
ophthalmic inflammation were graded following 
injections and implantation. Aqueous and 
vitreous protein levels, infiltrating cell counts, 
total number of T-lymphocytes, and levels of IL-2 
and IFNG-mRNA were significantly less in eyes 
containing the CsA device as compared to eyes 
with placebo. CsA devices did not completely 
eliminate recurrent experimental inflammatory 
episodes in the horse model; however, the 
duration and severity of inflammation, cellular 
infiltration, tissue destruction, and levels of 
pro-inflammatory cytokine RNA transcripts 
were significantly less in eyes implanted with 
the CsA devices. This study was focused on 
demonstrating the effectiveness of delivering 
CsA via an intraocular device for treatment of 
immune-mediated intraocular inflammation 
in an equine eye model. The flexibility of the 
device for delivering other drug molecules and 
its efficacy in other animal models or human 
subjects is yet to be reported.
In another study, glycolide-co-lactide-
co-caprolactone copolymer (PGLC) implants 
loaded with 2 mg CsA were tested in a rabbit 
model of uveitis. Eyes receiving these implants 
showed constant drug release for at least 14 
weeks along with reduction of intraocular 
inflammatory processes.31
INJECTABLE SYSTEMS
Verisome Delivery System
Icon Biosciences Inc. (Sunnyvale, CA, USA) is 
developing a promising drug delivery technology 
called Verisome. According to its manufacturer, 
this system can be used to release a broad range of 
pharmaceutical agents including small molecules, Drug Delivery Devices; Haghjou et al
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peptides, proteins, and monoclonal antibodies. 
The basic technology is highly versatile and 
can be formulated into numerous products, as 
a biodegradable solid, gel, or liquid substance 
that provide drug release in a controlled manner 
over some weeks to a year for ocular, systemic, 
or topical applications.32 Ophthalmic applications 
are focused on the ability of this system to 
create an injectable liquid or slightly viscous gel. 
Verisome-based products can be injected into 
the vitreous as a liquid via a standard 30-gauge 
needle (Fig. 7). When the drug is injected into the 
vitreous, it coalesces into a single spherule that 
settles inferiorly. The system is biodegradable 
and versatile for administering different drugs; 
furthermore duration of use can be tailored. 
Shrinkage of the Verisome spherule over 
time reflects simultaneous degradation of the 
delivery system and release of the active agent. 
In ophthalmology, this mode of delivery offers 
advantages because the physician can easily 
assess the status of therapy by observing the 
drug-containing system within the eye. When 
the spherule is no longer visible, the entire drug 
has been released, and no vehicle remains in the 
eye. In the future, flexibility of the system, along 
with the ability to directly monitor its status, 
may allow physicians to individually tailor the 
duration of drug delivery, potentially leading 
to cost efficiency and better results. Rather 
than having therapy dictated by the design of 
the delivery vehicle, physicians may be able to 
administer drugs with what they deem to be the 
appropriate duration and intensity of treatment 
for each patient.
In its first clinical trial, IBI 20089, the 
Verisome technology was formulated for delivery 
of TA.33 The injected gel forms a spherule in 
the posterior chamber after injection (Fig. 8) 
which gradually degrades and disappears as 
the drug is released. This liquid-gel formulation 
is designed to last up to 1 year, with duration 
determined by the volume injected. Follow-up 
visits to assess safety and efficacy of the drug 
delivery system included visual acuity and IOP 
measurements, optical coherence tomography, 
fundus photography and biomicroscopy. In the 
phase 1 study, Verisome was well tolerated and 
showed efficacy in patients with CME secondary 
to RVO. No injection-related adverse events or 
safety concerns were noted during the trial. 
Controlled-release biologic efficacy was also 
observed on sequential OCTs over 1 year. A 
phase 2-3 pivotal clinical study is anticipated 
to begin soon.
Cortiject Implant
The Cortiject implant (NOVA63035, Novagali 
Pharma) is a preservative- and solvent-free 
injectable emulsion based on the EYEJECT 
technology platform that contains a tissue-
activated corticosteroid prodrug. The prodrug 
is converted into the active agent by enzymes 
present in the target tissues, i.e. retina and 
choroid. These enzymes are not present in the 
vitreous or in the aqueous humor. The specific 
distribution of enzymes may avoid common 
corticosteroid related side effects such as 
glaucoma and cataract.
A single intravitreal injection of the 
emulsion provides sustained release of  Figure 7. Verisome delivery system.
Figure 8. Slit lamp photograph of the Verisome 
immediately after injection before it has settled down 
in the vitreous (A). Fundus photograph of the Verisome 
inside the eye, sitting below the visual axis (B).Drug Delivery Devices; Haghjou et al
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corticosteroid over a 6 to 9 month period. An 
open-label, phase 1, dose-escalation clinical 
study to assess the safety and tolerability of 
NOVA63035 in patients with DME is currently 
under way. The patients will be monitored for 
12 months following injection.
Particulate Drug Delivery Systems
Particulates are commonly classified into 
microparticles and nanoparticles based on size. 
Nanoparticles are colloidal particles ranging 
from 10 to 1,000 nm, in which drug may be 
entrapped, encapsulated, and/or absorbed. 
Microparticles are small drug-containing 
polymeric particles 1–10µm in size, which are 
suspended in a liquid carrier medium.
Microcapsules are spherical entities in 
which drug particles or droplets are entrapped 
in a polymeric membrane. Microspheres are 
a polymer–drug combination in which the 
drug is homogeneously dispersed within the 
polymeric matrix. Nanoparticles are divided 
into nanospheres where the drug is either 
incorporated within or attached to the surface, 
and nanocapsules that have a central cavity 
surrounded by a polymeric membrane.34 To 
avoid opsonisation and recognition by host 
phagocytes, the surface of the particles can be 
modified by pegylation.
De Kozak et al35 used polyethylene glycol-
coated cyanoacrylate nanoparticles loaded 
with tamoxifen for inhibition of intraocular 
inflammation in a rat model of EAU. These 
nanoparticles significantly inhibited the severity 
and extent of uveitis in treated eyes without 
any detectable ocular toxicity.
In-vivo studies on nanoparticles of 
piroxicam (a non-steroidal anti-inflammatory 
drug) using the solvent evaporation/extraction 
technique, and of methylprednisolone acetate 
(MPA) formulated using a copolymer of 
poly (ethylacrylate, methyl-methacrylate and 
chlorotrimethylammonioethyl-methacrylate) 
revealed that inflammation was inhibited by 
nanoparticles suspension more efficiently than 
microsuspension of the drug alone in rabbit 
eyes with EIU.36
Herrero-Vanrell and Refojo37 developed 
PLGA microspheres for sustained delivery of 
dexamethasone to prevent uveitis following 
surgical procedures. In their study, the 
inherent viscosity of PLGA (50% lactide-50% 
glycolide) was 0.2 dL/g and the proportion 
of dexamethasone in the polymer was 2/10. 
Ten milligrams of the microspheres contained 
1410µg of the active agent that was released 
in vitro for at least 45 days. The intravitreal 
half-life of dexamethasone administered via 
direct intravitreal injection is about 3.48 hours.38
Liposomes
During the last decade, the use of liposomes 
as a delivery system has become an attractive 
subject of research.39 Liposomes are small 
vesicles, typically ranging in size from 0.01 
to 10 mm, composed of a single phospholipid 
layer or concentric bilayers entrapping water in 
their center. They are formed by the dispersion 
of phospholipids in water and have been 
investigated since the 1970s as a means to 
achieve controlled and targeted drug delivery. 
Hydrophilic drugs can be entrapped within 
the aqueous core while lipophilic drugs may 
be incorporated into the lipid bilayers. Both of 
these integration processes can dramatically 
alter the biodistribution of liposomes.40
One study demonstrated the potential use 
of liposomes for intraocular drug delivery.41 
The authors evaluated the use of vasoactive 
intestinal peptide (VIP) for treatment of 
intravitreal inflammation. This neuropeptide 
interacts with many cell types associated 
with inflammation, including endothelial 
cells, macrophages and lymphocytes. In vitro, 
VIP inhibits the secretion of chemokines, 
nitric oxide and inflammatory cytokines. 
Additionally, it enhances the production of 
the anti-inflammatory cytokine IL-10. When 
bonded to liposomes, VIP has been used to 
treat arteritis and several other inflammatory 
conditions in experimental models.
In another study, rats with EIU were treated 
with an intravitreal injection of saline, saline 
containing VIP, liposomes containing VIP or 
unloaded liposomes.42 Twenty-four hours after 
treatment, VIP concentration in ocular fluids was Drug Delivery Devices; Haghjou et al
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15 times higher in eyes injected with liposomal 
VIP compared to the saline/VIP preparation. 
In VIP-liposome injected eyes, macrophages, 
and inflammatory cytokine and chemokine 
mRNA expression were significantly reduced 
as compared to the eyes injected with saline, 
saline-containing VIP or unloaded liposomes.
In another study, the authors investigated 
the effects of adding hyaluronic acid to a 
VIP liposomal delivery system.43 This study 
showed significant reduction in inflammation 
and suggested that the addition of hyaluronic 
acid further enhanced the efficacy and duration 
of effect of liposomal VIP. The prospect of an 
ocular anti-inflammatory medication that is not 
only effective but also lacks the conventional 
side effects of steroids is very encouraging.
TRANSSCERAL IONTOPHORESIS
Iontophoresis is an active method of drug 
delivery which employs a small electrical 
current to enhance diffusion of drug molecules 
across an intact sclera.44 As a non-invasive and 
well-tolerated method, iontophoresis has the 
potential to replace systemic administration 
and repeated intravitreal injections for posterior 
eye diseases.45 Eyegate (Optis Group, Paris, 
France) and OcuPhor (IOMED, Salt Lake City, 
USA) are two main ophthalmic iontophoresis 
systems under investigation.
The OcuPhor system consists of a drug 
applicator, a dispersive electrode, and an 
electronic iontophoresis dose controller. The 
drug applicator is a small silicone shell that 
contains a patented silver-silver chloride ink 
conductive element, a hydrogel pad to absorb 
the drug formulation, and a small flexible wire 
to connect the conductive element to the dose 
controller. The drug pad is hydrated with 
drug solution immediately prior to use, and 
the applicator is placed on the sclera under 
the lower eyelid (Fig. 9).
Eyegate consists of an annular silicone 
probe for transscleral iontophoresis with 0.5 
cm2 contact area and a 13 mm opening to avoid 
contact with the cornea (Fig. 10).
Iontophoretic delivery of anti-inflammatory 
drugs into the eye has been studied in humans 
and various animal models, and offers a viable 
alternative to topical or systemic administration.46
Lachaud47 used iontophoresis for delivery 
of hydrocortisone acetate (0.1% solution) into 
rabbit eyes using a current of 3 milliamperes 
(mA) for 10 minutes. The author demonstrated 
that iontophoresis could deliver higher 
concentrations of steroid into rabbit eyes than 
topical (0.5%), or subconjunctival (0.1mL, 
2.5%) routes. In human studies, Lachaud used 
iontophoresis to deliver dexamethasone acetate 
(7 mg, 1–2mA, 20 min) and treat a variety 
of clinical conditions, including idiopathic 
uveitis. The author reported that a significant 
proportion of patients with uveitis experienced 
Figure 9. OcuPhor iontophoresis system inserted in the 
human eye. Applicator is placed on the sclera under the 
lower eyelid.
Figure 10. Eyegate iontophoresis system applied on the 
human eye.Drug Delivery Devices; Haghjou et al
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more rapid recovery and/or increased comfort. 
Lachaud concluded that iontophoresis achieved 
therapeutic concentrations of the steroid(s) in 
ocular tissues. However, this open clinical study 
did not involve comparison with eyes receiving 
other therapies or with untreated control eyes.
Lam et al48 delivered 30% dexamethasone 
solution by transscleral iontophoresis into 
rabbit eyes using 1.6mA for 25 minutes. The 
diameter of the cylinder holding the drug 
solution in contact with the sclera was 0.7 mm. 
They compared peak steroid concentrations in 
the choroid and retina following iontophoresis, 
subconjunctival injection (1 mg) or retrobulbar 
injection (1 mg). Peak steroid concentration 
(mg/g tissue) was 122 for iontophoresis, 
18.1 for subconjunctival injection, and 6.6 for 
retrobulbar injection. In the vitreous humor, 
corresponding values were 140, 0.2, and 0.3 
mg/mL, respectively. Even 24 hours after 
iontophoresis, significant therapeutic levels of 
dexamethasone remained in the vitreous (3.3 
mg/mL) and in the choroid-retina (3.9 mg/g).
Eljarrat-Binstock et al49 achieved therapeutic 
dexamethasone levels in different eye segments 
using a lower current density (5.1mA/cm2) for 
only 4 minutes.
The efficacy of dexamethasone iontophoresis 
was studied in rat and rabbit models of EIU 
by Behar-Cohen et al50 and Hastings et al.51 
The first authors used a 6 mm diameter eye 
cup covering the cornea and sclera, while the 
latter investigators used a saturated hydrogel 
applicator in the superior cul-de-sac. The applied 
electrical current was 0.4mA (1.2 mA/cm2) 
for 4 minutes by Behar-Cohen et al, and 4mA 
for 20 minutes by Hastings et al. Both studies 
showed that administration of dexamethasone 
by iontophoresis inhibited anterior and posterior 
segment signs of intraocular inflammation as 
effectively as systemic administration. Cytokine 
(TNF-α) expression was inhibited in the anterior 
as well as the posterior segment. No clinical or 
histological damage was caused by iontophoresis. 
Thus, iontophoresis can deliver therapeutic doses 
of anti-inflammatory drugs to the posterior as 
well as the anterior segment of the eye and may 
be a viable alternative to systemic administration 
of steroids in severe ocular inflammation.
Recently, EyeGate Pharma announced 
the completion of a phase II study of EGP-
437 (dexamethasone phosphate ophthalmic 
solution optimized for iontophoresis) delivery 
using iontophoresis technology for treatment 
of anterior uveitis. The company submitted the 
anterior uveitis study results and data from a 
completed phase II study in dry eye patients to 
the FDA as part of an end-of-phase II meeting.
The EGP-437 phase II data is encouraging 
because it not only shows promising signs 
of efficacy but addresses compliance issues, 
by providing direct control of dosing. 
These positive results demonstrate that 
iontophoretically delivered drugs may offer 
new treatment options.
CONCLUSIONS
Uveitis is a potentially sight-threatening 
disease which has traditionally been treated 
with topical corticosteroids supplemented by 
periocular, intravitreal, and systemic steroids in 
severe cases. Chronic use of local and systemic 
corticosteroids can result in significant side 
effects that are sometimes life-threatening. 
Although newer immunosuppressive agents 
can reduce the amount of systemic steroids 
required for control of sight-threatening uveitis, 
most of these agents are poorly absorbed by 
the eye when applied topically and entail 
significant side effects. The chronic nature 
of uveitis also requires long-term patient 
compliance with prescribed medications. 
Sustained-release devices used for uveitis allow 
local delivery of immunosuppressive agents 
in adequate concentrations without systemic 
side effects. To date, for selected patients, 
potential complications associated with the 
insertion of these devices do not outweigh 
their advantages. However, miniaturization of 
the implants, allowing direct injection without 
need for complicated surgery, is a necessary 
development avenue. Particulate systems which 
can be engineered to target specific cells or 
tissues are another promising alternative.
A range of anti-inflammatory medications, 
some of which have been used systemically 
for uveitis and some have not, may be used Drug Delivery Devices; Haghjou et al
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in sustained-release devices in the future. 
Designing non-invasive sustained drug delivery 
systems and exploring the feasibility of topical 
application to deliver drugs to the posterior 
segment may drastically improve drug delivery 
in coming years. Future horizons could include 
devices containing complementary drugs and 
responsive sustained release delivery systems.
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